{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:00:14Z","timestamp":1789704014133,"version":"4.0.1"},"reference-count":86,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"abstract":"<jats:p>Background. The incidence of reported pertussis among adolescents, adults, and young infants has increased sharply over the past decade. Combined acellular pertussis vaccines for adolescents and adults are available in Canada, Australia, and Germany and may soon be considered for use in the United States.<\/jats:p><jats:p>Objective. To evaluate the potential health benefits, risks, and costs of a national pertussis vaccination program for adolescents and\/or adults.<\/jats:p><jats:p>Design, Setting, and Population. The projected health states and immunity levels associated with pertussis disease and vaccination were simulated with a Markov model. The following strategies were examined from the health care payer and societal perspectives: (1) no vaccination; (2) 1-time adolescent vaccination; (3) 1-time adult vaccination; (4) adult vaccination with boosters; (5) adolescent and adult vaccination with boosters; and (6) postpartum vaccination. Data on disease incidence, costs, outcomes, vaccine efficacy, and adverse events were based on published studies, recent unpublished clinical trials, and expert panel input.<\/jats:p><jats:p>Main Outcome Measures. Cases prevented, adverse events, costs (in 2004 US dollars), cost per case prevented, and cost per quality-adjusted life-year (QALY) saved.<\/jats:p><jats:p>Results. One-time adolescent vaccination would prevent 30800 cases of pertussis (36% of projected cases) and would result in 91000 vaccine adverse events (67% local reactions). If pertussis vaccination cost $15 and vaccine coverage was 76%, then 1-time adolescent vaccination would cost $1100 per case prevented (or $1200 per case prevented) or $20000 per QALY (or $23000 per QALY) saved, from the societal (or health care payer) perspective. With a threshold of $50000 per QALY saved, the adolescent and adult vaccination with boosters strategy became potentially cost-effective from the societal perspective only if 2 conditions were met simultaneously, ie, (1) the disease incidence for adolescents and adults was \u22656 times higher than base-case assumptions and (2) the cost of vaccination was less than $10. Adult vaccination strategies were more costly and less effective than adolescent vaccination strategies. The results were sensitive to assumptions about disease incidence, vaccine efficacy, frequency of vaccine adverse events, and vaccine costs.<\/jats:p><jats:p>Conclusions. Routine pertussis vaccination of adolescents results in net health benefits and may be relatively cost-effective.<\/jats:p>","DOI":"10.1542\/peds.2004-2509","type":"journal-article","created":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T17:19:46Z","timestamp":1117646386000},"page":"1675-1684","source":"Crossref","is-referenced-by-count":104,"title":["Pertussis in Adolescents and Adults: Should We Vaccinate?"],"prefix":"10.1542","volume":"115","author":[{"given":"Grace M.","family":"Lee","sequence":"first","affiliation":[{"name":"Center for Child Health Care Studies, Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts"},{"name":"Divisions of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"LeBaron","sequence":"additional","affiliation":[{"name":"National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy V.","family":"Murphy","sequence":"additional","affiliation":[{"name":"National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lett","sequence":"additional","affiliation":[{"name":"Massachusetts Department of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Schauer","sequence":"additional","affiliation":[{"name":"Massachusetts Department of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy A.","family":"Lieu","sequence":"additional","affiliation":[{"name":"Center for Child Health Care Studies, Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts"},{"name":"General Pediatrics, Children's Hospital Boston, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,6,1]]},"reference":[{"key":"2021120819235919000_R1","doi-asserted-by":"crossref","unstructured":"Farizo KM, Cochi SL, Zell ER, et al. Epidemiological features of pertussis in the United States, 1980\u20131989. Clin Infect Dis.\u20081992;14:708\u2013719","DOI":"10.1093\/clinids\/14.3.708"},{"key":"2021120819235919000_R2","doi-asserted-by":"crossref","unstructured":"Yih WK, Lett SM, des Vignes FN et al. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989\u20131998. J Infect Dis.\u20082000;182:1409\u20131416","DOI":"10.1086\/315863"},{"key":"2021120819235919000_R3","unstructured":"Centers for Disease Control and Prevention. Pertussis: United States, 1997\u20132000. MMWR Morb Mortal Wkly Rep.\u20082002;51:73\u201376"},{"key":"2021120819235919000_R4","doi-asserted-by":"crossref","unstructured":"Black S. Epidemiology of pertussis. Pediatr Infect Dis J.\u20081997;16(suppl):S85\u2013S89","DOI":"10.1097\/00006454-199704001-00003"},{"key":"2021120819235919000_R5","doi-asserted-by":"crossref","unstructured":"Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990\u20131996. Clin Infect Dis.\u20081999;28:1230\u20131237","DOI":"10.1086\/514776"},{"key":"2021120819235919000_R6","unstructured":"Bisgard KM, Rhodes P, Connelly BL, et al. Pertussis vaccine effectiveness among children aged 6\u201359 months in the United States, 1998\u20132001. Presented at the 41st Annual Meeting of the Infectious Diseases Society of America; October 9\u201312, 2003; San Diego, CA"},{"key":"2021120819235919000_R7","unstructured":"Centers for Disease Control and Prevention. National, state, and urban area vaccination levels among children aged 19\u201335 months: United States, 2002. MMWR Morb Mortal Wkly Rep.\u20082003;52:728\u2013732"},{"key":"2021120819235919000_R8","doi-asserted-by":"crossref","unstructured":"Mink CM, Cherry JD, Christenson P, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis.\u20081992;14:464\u2013471","DOI":"10.1093\/clinids\/14.2.464"},{"key":"2021120819235919000_R9","doi-asserted-by":"crossref","unstructured":"Nennig ME, Shinefield HR, Edwards KM, et al. Prevalence and incidence of adult pertussis in an urban population. JAMA.\u20081996;275:1672\u20131674","DOI":"10.1001\/jama.275.21.1672"},{"key":"2021120819235919000_R10","doi-asserted-by":"crossref","unstructured":"Wright SW, Edwards KM, Decker MD, et al. Pertussis infection in adults with persistent cough. JAMA.\u20081995;273:1044\u20131046","DOI":"10.1001\/jama.273.13.1044"},{"key":"2021120819235919000_R11","doi-asserted-by":"crossref","unstructured":"Senzilet LD, Halperin SA, Spika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis.\u20082001;32:1691\u20131697","DOI":"10.1086\/320754"},{"key":"2021120819235919000_R12","doi-asserted-by":"crossref","unstructured":"Marchant CD, Loughlin AM, Lett SM, et al. Pertussis in Massachusetts, 1981\u20131991: incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis.\u20081994;169:1297\u20131305","DOI":"10.1093\/infdis\/169.6.1297"},{"key":"2021120819235919000_R13","doi-asserted-by":"crossref","unstructured":"Skowronski DM, De Serres G, MacDonald D, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis.\u20082002;185:1448\u20131453","DOI":"10.1086\/340280"},{"key":"2021120819235919000_R14","doi-asserted-by":"crossref","unstructured":"Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed).\u20081988;296:612\u2013614","DOI":"10.1136\/bmj.296.6622.612"},{"key":"2021120819235919000_R15","doi-asserted-by":"crossref","unstructured":"Lambert HJ. Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep.\u20081965;80:365\u2013367","DOI":"10.2307\/4592424"},{"key":"2021120819235919000_R16","doi-asserted-by":"crossref","unstructured":"De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis.\u20082000;182:174\u2013179","DOI":"10.1086\/315648"},{"key":"2021120819235919000_R17","doi-asserted-by":"crossref","unstructured":"Thomas PF, McIntyre PB, Jalaludin BB. Survey of pertussis morbidity in adults in western Sydney. Med J Aust.\u20082000;173:74\u201376","DOI":"10.5694\/j.1326-5377.2000.tb139246.x"},{"key":"2021120819235919000_R18","doi-asserted-by":"crossref","unstructured":"Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis.\u20082004;39:1572\u20131580","DOI":"10.1086\/425006"},{"key":"2021120819235919000_R19","doi-asserted-by":"crossref","unstructured":"Postels-Multani S, Schmitt HJ, Wirsing von Konig CH, et al. Symptoms and complications of pertussis in adults. Infection.\u20081995;23:139\u2013142","DOI":"10.1007\/BF01793853"},{"key":"2021120819235919000_R20","doi-asserted-by":"crossref","unstructured":"Vitek CR, Pascual FB, Baughman AL, et al. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J.\u20082003;22:628\u2013634","DOI":"10.1097\/01.inf.0000073266.30728.0e"},{"key":"2021120819235919000_R21","doi-asserted-by":"crossref","unstructured":"Tanaka M, Vitek CR, Pascual FB, et al. Trends in pertussis among infants in the United States, 1980\u20131999. JAMA.\u20082003;290:2968\u20132975","DOI":"10.1001\/jama.290.22.2968"},{"key":"2021120819235919000_R22","doi-asserted-by":"crossref","unstructured":"Orenstein WA. Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination. Clin Infect Dis.\u20081999;28(suppl 2):S147\u2013S150","DOI":"10.1086\/515061"},{"key":"2021120819235919000_R23","doi-asserted-by":"crossref","unstructured":"Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis.\u20081999;28(suppl 2):S112\u2013S117","DOI":"10.1086\/515058"},{"key":"2021120819235919000_R24","doi-asserted-by":"crossref","unstructured":"Nelson JD. The changing epidemiology of pertussis in young infants: the role of adults as reservoirs of infection. Am J Dis Child.\u20081978;132:371\u2013373","DOI":"10.1001\/archpedi.1978.02120290043006"},{"key":"2021120819235919000_R25","doi-asserted-by":"crossref","unstructured":"Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis.\u20081990;161:480\u2013486","DOI":"10.1093\/infdis\/161.3.480"},{"key":"2021120819235919000_R26","doi-asserted-by":"crossref","unstructured":"Mertsola J, Ruuskanen O, Eerola E, et al. Intrafamilial spread of pertussis. J Pediatr.\u20081983;103:359\u2013363","DOI":"10.1016\/S0022-3476(83)80403-X"},{"key":"2021120819235919000_R27","doi-asserted-by":"crossref","unstructured":"Izurieta HS, Kenyon TA, Strebel PM, et al. Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. Clin Infect Dis.\u20081996;22:503\u2013507","DOI":"10.1093\/clinids\/22.3.503"},{"key":"2021120819235919000_R28","doi-asserted-by":"crossref","unstructured":"Wirsing von Konig CH, Postels-Multani S, Bogaerts H, et al. Factors influencing the spread of pertussis in households. Eur J Pediatr.\u20081998;157:391\u2013394","DOI":"10.1007\/s004310050836"},{"key":"2021120819235919000_R29","doi-asserted-by":"crossref","unstructured":"Deen JL, Mink CA, Cherry JD, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis.\u20081995;21:1211\u20131219","DOI":"10.1093\/clinids\/21.5.1211"},{"key":"2021120819235919000_R30","unstructured":"National Advisory Committee on Immunization. Prevention of pertussis in adolescents and adults. Can Commun Dis Rep.\u20082003;29:1\u20139"},{"key":"2021120819235919000_R31","unstructured":"De Serres G. An Advisory Committee Statement (ASC): National Advisory Committee on Immunization (NACI): statement on adult\/adolescent formulation of combined acellular pertussis, tetanus, and diphtheria vaccine. Can Commun Dis Rep.\u20082000;26:1\u20138"},{"key":"2021120819235919000_R32","doi-asserted-by":"crossref","unstructured":"Campins-Marti M, Cheng HK, Forsyth K, et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine.\u20082001;20:641\u2013646","DOI":"10.1016\/S0264-410X(01)00393-0"},{"key":"2021120819235919000_R33","unstructured":"Australian Government, Department of Health and Aging. The Australian Immunisation Handbook: fact sheet for immunisation providers. Available at: www.immunise.health.gov.au\/nip\/fact_provider.pdf. Accessed December 30, 2003"},{"key":"2021120819235919000_R34","unstructured":"GlaxoSmithKline. GSK vaccines by country. Available at: www.worldwidevaccines.com\/by_country\/gsk_vaccines.asp. Accessed January 14, 2004"},{"key":"2021120819235919000_R35","doi-asserted-by":"crossref","unstructured":"Chapman TM, Goa KL. Reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine (Boostrix). Drugs.\u20082003;63:1407\u20131413","DOI":"10.2165\/00003495-200363130-00005"},{"key":"2021120819235919000_R36","doi-asserted-by":"crossref","unstructured":"Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine.\u20082000;19:628\u2013636","DOI":"10.1016\/S0264-410X(00)00252-8"},{"key":"2021120819235919000_R37","doi-asserted-by":"crossref","unstructured":"Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine.\u20082000;18:2075\u20132082","DOI":"10.1016\/S0264-410X(99)00568-X"},{"key":"2021120819235919000_R38","doi-asserted-by":"crossref","unstructured":"Halperin SA, Smith B, Russell M, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine.\u20082000;18:1312\u20131319","DOI":"10.1016\/S0264-410X(99)00415-6"},{"key":"2021120819235919000_R39","doi-asserted-by":"crossref","unstructured":"Minh NN, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics.\u20081999;104(6). Available at: www.pediatrics.org\/cgi\/content\/full\/104\/6\/e70","DOI":"10.1542\/peds.104.6.e70"},{"key":"2021120819235919000_R40","doi-asserted-by":"crossref","unstructured":"Halperin SA, Smith B, Russell M, et al. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J.\u20082000;19:276\u2013283","DOI":"10.1097\/00006454-200004000-00003"},{"key":"2021120819235919000_R41","unstructured":"Ward J. The APERT Study. Presented at the National Consensus Conference on Pertussis; May 25\u201328, 2002; Toronto, Canada"},{"key":"2021120819235919000_R42","unstructured":"Ward JI, APERT Study Group. Pertussis epidemiology and acellular pertussis vaccine efficacy in older children: NIH APERT Multicenter Pertussis Trial. Presented at the Pediatric Academic Societies Annual Meeting; April 28\u2013May 1, 2001; Baltimore, MD"},{"key":"2021120819235919000_R43","doi-asserted-by":"crossref","unstructured":"Thomas MG, Lambert HP. From whom do children catch pertussis?Br Med J (Clin Res Ed).\u20081987;295:751\u2013752","DOI":"10.1136\/bmj.295.6601.751"},{"key":"2021120819235919000_R44","doi-asserted-by":"crossref","unstructured":"Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis.\u20082003;14:196\u2013198","DOI":"10.1016\/S1045-1870(03)00033-5"},{"key":"2021120819235919000_R45","doi-asserted-by":"crossref","unstructured":"Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics.\u20082000;105(1). Available at: www.pediatrics.org\/cgi\/content\/full\/105\/1\/e12","DOI":"10.1542\/peds.105.1.e12"},{"key":"2021120819235919000_R46","doi-asserted-by":"crossref","unstructured":"Skowronski DM, Remple VP, Macnabb J, et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics.\u20082003;112(6). Available at: www.pediatrics.org\/cgi\/content\/full\/112\/6\/e453","DOI":"10.1542\/peds.112.6.e453"},{"key":"2021120819235919000_R47","doi-asserted-by":"crossref","unstructured":"Gold MS, Noonan S, Osbourn M, et al. Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. Med J Aust.\u20082003;179:191\u2013194","DOI":"10.5694\/j.1326-5377.2003.tb05497.x"},{"key":"2021120819235919000_R48","doi-asserted-by":"crossref","unstructured":"Jackson LA, Carste BA, Malais D, et al. Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr Infect Dis J.\u20082002;21:781\u2013786","DOI":"10.1097\/00006454-200208000-00016"},{"key":"2021120819235919000_R49","doi-asserted-by":"crossref","unstructured":"Wirsing von Konig CH, Postels-Multani S, Bock HL, et al. Pertussis in adults: frequency of transmission after household exposure. Lancet.\u20081995;346:1326\u20131329","DOI":"10.1016\/S0140-6736(95)92343-8"},{"key":"2021120819235919000_R50","doi-asserted-by":"crossref","unstructured":"Cattaneo LA, Reed GW, Haase DH, et al. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1\u201365 years. J Infect Dis.\u20081996;173:1256\u20131259","DOI":"10.1093\/infdis\/173.5.1256"},{"key":"2021120819235919000_R51","doi-asserted-by":"crossref","unstructured":"Ramsay ME, Farrington CP, Miller E. Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol Infect.\u20081993;111:41\u201348","DOI":"10.1017\/S095026880005665X"},{"key":"2021120819235919000_R52","unstructured":"National Aeronautics and Space Administration. Gross domestic product deflator inflation calculator. Available at: www.jsc.nasa.gov\/bu2\/inflateGDP.html. Accessed October 30, 2004"},{"key":"2021120819235919000_R53","doi-asserted-by":"crossref","unstructured":"Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"2021120819235919000_R54","unstructured":"TreeAge Software. Data Professional. Williamstown, MA: TreeAge Software; 2002"},{"key":"2021120819235919000_R55","doi-asserted-by":"crossref","unstructured":"Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995\u20131996. J Infect Dis.\u20082001;183:1353\u20131359","DOI":"10.1086\/319853"},{"key":"2021120819235919000_R56","unstructured":"Centers for Disease Control and Prevention. National Health Interview Survey, United States. Available at: www.cdc.gov\/nip\/coverage\/NHIS\/tables\/general-99.pdf. Accessed December 30, 2003"},{"key":"2021120819235919000_R57","doi-asserted-by":"crossref","unstructured":"Garcia DG, Ewert DP, Mascola L. A survey of hospital postpartum and postabortion rubella vaccination policies in Los Angeles County, 1992. Infect Control Hosp Epidemiol.\u20081993;14:513\u2013516","DOI":"10.1086\/646795"},{"key":"2021120819235919000_R58","unstructured":"Centers for Disease Control and Prevention. Rubella vaccination during pregnancy: United States, 1971\u20131981. MMWR Morb Mortal Wkly Rep.\u20081982;31:477\u2013481"},{"key":"2021120819235919000_R59","doi-asserted-by":"crossref","unstructured":"Leber JL. Rubella immunization risk postpartum. JAMA.\u20081971;217:697","DOI":"10.1001\/jama.1971.03190050153022"},{"key":"2021120819235919000_R60","doi-asserted-by":"crossref","unstructured":"Schrag SJ, Arnold KE, Mohle-Boetani JC, et al. Prenatal screening for infectious diseases and opportunities for prevention. Obstet Gynecol.\u20082003;102:753\u2013760","DOI":"10.1097\/00006250-200310000-00017"},{"key":"2021120819235919000_R61","doi-asserted-by":"crossref","unstructured":"van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine.\u20082004;22:3154\u20133165","DOI":"10.1016\/j.vaccine.2004.01.067"},{"key":"2021120819235919000_R62","doi-asserted-by":"crossref","unstructured":"Dolan P. Output measures and valuation in health. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care. Oxford, United Kingdom: Oxford University Press; 2001:46\u201367","DOI":"10.1093\/oso\/9780192631770.003.0003"},{"key":"2021120819235919000_R63","doi-asserted-by":"crossref","unstructured":"Richardson J. Cost utility analysis: what should be measured?Soc Sci Med.\u20081994;39:7\u201321","DOI":"10.1016\/0277-9536(94)90162-7"},{"key":"2021120819235919000_R64","doi-asserted-by":"crossref","unstructured":"Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ.\u20081986;5:1\u201330","DOI":"10.1016\/0167-6296(86)90020-2"},{"key":"2021120819235919000_R65","doi-asserted-by":"crossref","unstructured":"Tozzi AE, Rava L, Ciofi degli Atti ML et al. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics.\u20082003;112:1069\u20131075","DOI":"10.1542\/peds.112.5.1069"},{"key":"2021120819235919000_R66","unstructured":"Centers for Medicare and Medicaid Services. Medicare program: changes to the hospital inpatient prospective payment systems and rates and costs of graduate medical education: fiscal year 2002 rates: provisions of the Balanced Budget Refinement Act of 1999 and provisions of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000. Fed Regist. August 1, 2001;66:39828\u201340102"},{"key":"2021120819235919000_R67","unstructured":"Centers for Medicare and Medicaid Services. Medicare program; changes to the hospital outpatient prospective payment system for calendar year 2002. Fed Regist. November 30, 2001;66:59856\u201360125"},{"key":"2021120819235919000_R68","unstructured":"Centers for Medicare and Medicaid Services. Medicare program: revisions to payment policies and five-year review of and adjustments to the relative value units under the physician fee schedule for calendar year 2002. Fed Regist. November 1, 2001;66:55246\u201355503"},{"key":"2021120819235919000_R69","unstructured":"Morris M, Tang S. Pediatric Service Utilization, Fees and Managed Care Arrangements, 2001 Report Based on 1999 Data. Elk Grove Village, IL: American Academy of Pediatrics; 2001"},{"key":"2021120819235919000_R70","doi-asserted-by":"crossref","unstructured":"Mikelova LK, Halperin SA, Scheifele D, et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr.\u20082003;143:576\u2013581","DOI":"10.1067\/S0022-3476(03)00365-2"},{"key":"2021120819235919000_R71","unstructured":"US Census Bureau. Income 2000. Available at: www.census.gov\/hhes\/income\/income00\/inctab7.html. Accessed November 18, 2003"},{"key":"2021120819235919000_R72","unstructured":"Arrow Pharmaceuticals. Australian pharmaceutical industry. Available at: www.arrowpharma.com\/about.cfm. Accessed November 11, 2003"},{"key":"2021120819235919000_R73","unstructured":"Bundaberg and District, Division of General Practice. Immunisation issues. Available at: www.widebaydgp.org.au\/News\/newslett\/Sept-Oct2002a.pdf. Accessed November 11, 2003"},{"key":"2021120819235919000_R74","doi-asserted-by":"crossref","unstructured":"Stone PW, Teutsch S, Chapman RH, et al. Cost-utility analyses of clinical preventive services: published ratios, 1976\u20131997. Am J Prev Med.\u20082000;19:15\u201323","DOI":"10.1016\/S0749-3797(00)00151-3"},{"key":"2021120819235919000_R75","doi-asserted-by":"crossref","unstructured":"Chapman RH, Stone PW, Sandberg EA, et al. A comprehensive league table of cost-utility ratios and a sub-table of \u201cpanel-worthy\u201d studies. Med Decis Making.\u20082000;20:451\u2013467","DOI":"10.1177\/0272989X0002000409"},{"key":"2021120819235919000_R76","doi-asserted-by":"crossref","unstructured":"Pignone M, Saha S, Hoerger T, et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med.\u20082002;137:96\u2013104","DOI":"10.7326\/0003-4819-137-2-200207160-00007"},{"key":"2021120819235919000_R77","doi-asserted-by":"crossref","unstructured":"Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making.\u20082002;22:417\u2013430","DOI":"10.1177\/027298902320556118"},{"key":"2021120819235919000_R78","doi-asserted-by":"crossref","unstructured":"Zhou F, Bisgard KM, Yusuf HR, et al. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics.\u20082002;110:653\u2013661","DOI":"10.1542\/peds.110.4.653"},{"key":"2021120819235919000_R79","doi-asserted-by":"crossref","unstructured":"Zhou F, Reef S, Massoudi M, et al. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. J Infect Dis.\u20082004;189(suppl 1):S131\u2013S145","DOI":"10.1086\/378987"},{"key":"2021120819235919000_R80","doi-asserted-by":"crossref","unstructured":"Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA.\u20082000;283:1460\u20131468","DOI":"10.1001\/jama.283.11.1460"},{"key":"2021120819235919000_R81","doi-asserted-by":"crossref","unstructured":"Prosser LA, Ray GT, O'Brien M, et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics.\u20082004;113:283\u2013290","DOI":"10.1542\/peds.113.2.283"},{"key":"2021120819235919000_R82","doi-asserted-by":"crossref","unstructured":"Purdy KW, Hay JW, Botteman MF, et al. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis.\u20082004;39:20\u201328","DOI":"10.1086\/421091"},{"key":"2021120819235919000_R83","doi-asserted-by":"crossref","unstructured":"Woo EJ, Burwen DR, Gatumu SN, et al. Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System. Clin Infect Dis.\u20082003;37:351\u2013358","DOI":"10.1086\/375820"},{"key":"2021120819235919000_R84","doi-asserted-by":"crossref","unstructured":"Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics.\u20082003;112:815\u2013820","DOI":"10.1542\/peds.112.4.815"},{"key":"2021120819235919000_R85","doi-asserted-by":"crossref","unstructured":"Lee GM, Salomon JA, LeBaron CW, et al. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes.\u20082005;3:17","DOI":"10.1186\/1477-7525-3-17"},{"key":"2021120819235919000_R86","unstructured":"Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS): United States, 1991\u20132001. MMWR Surveill Summ.\u20082003;52:1\u201324"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/6\/1675\/1027421\/zpe00605001675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/6\/1675\/1027421\/zpe00605001675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T11:39:52Z","timestamp":1706269192000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/115\/6\/1675\/67491\/Pertussis-in-Adolescents-and-Adults-Should-We"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":86,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,6,1]]},"published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-2509","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,1]]}}}